4//SEC Filing
AzurRx BioPharma, Inc. 4
Accession 0001415889-17-000958
$GRDXCIK 0001604191operating
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 4:44 PM ET
Size
12.0 KB
Accession
0001415889-17-000958
Insider Transaction Report
Form 4
Ross Edmund Burke Jr.
10% Owner
Transactions
- Purchase
Common Stock
2017-06-05$3.50/sh+128,572$450,002→ 1,659,840 total(indirect: See Footnote) - Purchase
Series A Warrants
2017-06-05+128,572→ 32,143 totalExercise: $4.00From: 2017-06-05Exp: 2017-12-31→ Common Stock (32,143 underlying) - Purchase
Series A-1 Warrants
2017-06-05+128,572→ 96,429 totalExercise: $5.50From: 2017-12-05Exp: 2022-06-05→ Common Stock (96,429 underlying)
Footnotes (4)
- [F1]Entities associated with Mr. Ross purchased Units for a price of $3.50 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase 1/4 share of common Stock, and one Series A-1 Warrant to purchase 3/4 share of common stock from AzurRx BioPharma, Inc. in a private placement exempt from registration under the Securities Act of 1933, as amended.
- [F2]Of the 128,572 shares of common stock, 100,000 were purchased by EBR Ventures, LLC and 28,572 were purchased by CEDA Investments, LLC.
- [F3]Of the 1,659,840 shares of common stock beneficially owned, 1,031,268 are held by ADEC Private Equity Investment, LLC, 600,000 are held by EBR Ventures, LLC, and 28,572 are held by CEDA Investments, LLC. Mr. Ross holds sole voting and dispositive power over the shares of Common stock and each of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, and CEDA Investments, LLC disclaims beneficial ownership of the applicable shares of common stock, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that any of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, or CEDA Investments, LLC is the beneficial owner of such shares of common stock for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F4]Of the Series A Warrants, warrants to purchase 25,000 shares of common stock were purchased by EBR Ventures, LLC, and warrants to purchase 7,143 shares of common stock were purchased by CEDA Investments, LLC. Of the Series A-1 Warrants, warrants to purchase 75,000 shares of common stock were purchased by EBR Ventures, LLC, and warrants to purchase 21,429 shares of common stock were purchased by CEDA Investments, LLC. Mr. Ross holds sole voting and dispositive power over the shares of common stock and each of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, and CEDA Investments, LLC disclaims beneficial ownership of such securities underlying the warrants, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that any of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, or CEDA Investments, LLC is the beneficial owner of such securities for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
AzurRx BioPharma, Inc.
CIK 0001604191
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001604191
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 4:44 PM ET
- Size
- 12.0 KB